Ballew Advisors’s PTC Therapeutics PTCT Stock Holding History

Ballew Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-6	Closed	–	–	358
2018 Q3	$0	Buy	+6	New	+$248	﹤0.01%	510

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Ballew Advisors's PTCT Position: Q4 2018 in Review

Ballew Advisors sold out of PTC Therapeutics (PTCT) in Q4 2018, closing a stake of 6 shares.

Ballew Advisors first reported a position in PTCT in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 164 funds tracked by Wall St. Rank hold PTCT as of Q4 2018.

Ballew Advisors reported no remaining PTC Therapeutics position as of Q4 2018 after selling out during the quarter.
Ballew Advisors sold 6 PTC Therapeutics shares in Q4 2018.
Ballew Advisors first reported a position in PTC Therapeutics in Q3 2018 and held it in 1 quarter.
Ballew Advisors's PTC Therapeutics position peaked at $0 in Q3 2018.
164 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.